Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai ZJ Bio-Tech CoSHSE:688317 -0.64%64 Cash-to-Debt is 9.53 as of Mar. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates SHSE:688317 with a GF Score™ of 64/100 and a GF Value™ of ¥9.61 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 844 Medical Devices & Instruments companies, Shanghai ZJ Bio-Tech Co ranks better than 74.29% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Shanghai ZJ Bio-Tech Co's cash to debt ratio for the quarter that ended in Mar. 2026 was 9.53.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Shanghai ZJ Bio-Tech Cocould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Shanghai ZJ Bio-Tech Co's Cash-to-Debt or its related term are showing as below:
SHSE:688317'
s Cash-to-Debt Range Over the Past 10 Years
Min: 9.53 Med: No Debt Max: No Debt
Current: 9.53
During the past 13 years, Shanghai ZJ Bio-Tech Co's highest Cash to Debt Ratio was No Debt. The lowest was 9.53. And the median was No Debt.
SHSE:688317's Cash-to-Debt is ranked better than 74.29% of 844
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs SHSE:688317: 9.53
Shanghai ZJ Bio-Tech Co (SHSE:688317) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Shanghai ZJ Bio-Tech Co Cash-to-Debt Related Terms
Shanghai ZJ Bio-Tech Co Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
SHSE:688317 vs ABT, SYK, MDT: Cash-to-Debt Comparison
For the Medical Devices subindustry, Shanghai ZJ Bio-Tech Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai ZJ Bio-Tech Co Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai ZJ Bio-Tech Co's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Shanghai ZJ Bio-Tech Co's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai ZJ Bio-Tech Co (SHSE:688317) has a Cash-to-Debt of 9.53 as of Mar. 2026. This is 100% below median its historical median of 10,000.00. Over the past decade, Shanghai ZJ Bio-Tech Co's Cash-to-Debt has ranged from 9.53 to 10,000.00. According to the industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #217 out of 844 companies in the Medical Devices & Instruments industry, placing it in the top 25.7%.
Is Shanghai ZJ Bio-Tech Co's Cash-to-Debt too high?
Shanghai ZJ Bio-Tech Co's current Cash-to-Debt of 9.53 is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 9.53 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.63. Shanghai ZJ Bio-Tech Co's value of 9.53 is 484.7% above this industry median. Based on the distribution chart, Shanghai ZJ Bio-Tech Co ranks #217 out of 844 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shanghai ZJ Bio-Tech Co has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai ZJ Bio-Tech Co's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #217 out of 844 companies for Cash-to-Debt. This puts Shanghai ZJ Bio-Tech Co in the upper half of its industry. The industry median Cash-to-Debt is 1.63. Shanghai ZJ Bio-Tech Co's value of 9.53 is 484.7% above this benchmark. Historically, Shanghai ZJ Bio-Tech Co's own Cash-to-Debt has ranged from 9.53 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 1.63, Shanghai ZJ Bio-Tech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.63, based on 844 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai ZJ Bio-Tech Co's current Cash-to-Debt of 9.53 is 484.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai ZJ Bio-Tech Co's current Cash-to-Debt is 9.53, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai ZJ Bio-Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co (SHSE:688317) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥9.61, compared to a current price of ¥17.20 — trading 79% above its estimated fair value. The current Cash-to-Debt is 9.53, which is 100% below median its 10-year median of 10,000.00 and 484.7% above the Medical Devices & Instruments industry median of 1.63. Shanghai ZJ Bio-Tech Co's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Shanghai ZJ Bio-Tech Co (SHSE:688317), the current Cash-to-Debt is 9.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai ZJ Bio-Tech Co (SHSE:688317) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co stock appears to be overvalued.
The current stock price of ¥17.20 is trading 79% above its estimated GF Value™ of ¥9.61.
GuruFocus considers Shanghai ZJ Bio-Tech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688317:
Cash-to-Debt: 9.53 (100% below median its 10-year median of 10,000.00)
GF Value™: ¥9.61 vs. price of ¥17.20 (79% above fair value)
Industry Position: 484.7% above the Medical Devices & Instruments median (#217 of 844)
No single metric tells the full story. See the SHSE:688317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.
64GF Score
Get the complete analysis for SHSE:688317
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688317 has been successfully added to your 
